Text Size

Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD

This study has been completed.
Sponsor:
Information provided by:
Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier:
NCT00629044
First received: February 25, 2008
Last updated: March 25, 2011
Last verified: August 2009
History of Changes

February 25, 2008
March 25, 2011
November 2007
November 2009   (final data collection date for primary outcome measure)
To know if cholesterol 24 S hydroxylase and 24 hydroxycholesterol are involve in Glaucoma and AMD [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00629044 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD
Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.

The aim of this study is to assess the implicitement of the cholesterol 24 S hydroxylase gene and the 24 S hydroxycholesterol in glaucoma and in age related macular degeneration.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
Glaucoma
  • Biological: Assessing the blood level of cholesterol 24 S Hydroxylase
    Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
  • Biological: Assessing the blood level of cholesterol 24 S hydroxylase
    Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
  • Biological: assessing the blood level of cholesterol 24 S hydroxylase
    Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
  • Active Comparator: G
    Intervention: Biological: Assessing the blood level of cholesterol 24 S Hydroxylase
  • Active Comparator: AMD
    Intervention: Biological: Assessing the blood level of cholesterol 24 S hydroxylase
  • Active Comparator: Healthy subjects
    Intervention: Biological: assessing the blood level of cholesterol 24 S hydroxylase
Joffre C, Souchier M, Grégoire S, Viau S, Bretillon L, Acar N, Bron AM, Creuzot-Garcher C. Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye. Br J Ophthalmol. 2008 Jan;92(1):116-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
320
January 2011
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient with Glaucoma
  • Patient with AMD
  • Healthy patient

Exclusion Criteria:

  • All patients who use any treatment in order to maintain in normal value their blood cholesterol
Both
40 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00629044
PHRC IR 2006
Yes
Professor Catherine Creuzot-Garcher, CHU Dijon
Centre Hospitalier Universitaire Dijon
Not Provided
Principal Investigator: Catherine Creuzot-Gracher, MD, PhD CHU Dijon
Centre Hospitalier Universitaire Dijon
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP